Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + Quinacrine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Quinacrine||Acrichine||Quinacrine Dihydrochloride||Acrichine (quinacrine) inhibits the transcription and activity of NF-kappaB, which may result in the induction of tumor suppressor p53 transcription and tumor cell apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Fluorouracil + Quinacrine||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Acrichine (quinacrine) and Adrucil (5-fluorouracil) synergized to inhibit tumor growth in colorectal cancer cell line xenograft models (PMID: 21725213).||21725213|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|